You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

 

Online download statistics by month:

Online download statistics by month: June 2020 to June 2025

AbstractFullPdf
Jun 2020573573319
Jul 202022922989
Aug 202010010036
Sep 202010210249
Oct 2020767632
Nov 2020686819
Dec 2020929236
Jan 202112312364
Feb 202112312630
Mar 202119319341
Apr 202123523553
May 202116116133
Jun 202117317368
Jul 202114214243
Aug 202111611633
Sep 202114314342
Oct 202113613654
Nov 202115715853
Dec 202117618044
Jan 202214114825
Feb 202211011333
Mar 202216017547
Apr 202215516655
May 202215917451
Jun 202215415842
Jul 202214114829
Aug 202212512833
Sep 202211912043
Oct 202212413439
Nov 202211912131
Dec 2022989822
Jan 202312312434
Feb 202315115225
Mar 202310310413
Apr 202311311424
May 202311912124
Jun 202310510515
Jul 202310210227
Aug 202310410430
Sep 202310610615
Oct 2023727518
Nov 2023808121
Dec 2023949517
Jan 2024505121
Feb 2024626223
Mar 2024888830
Apr 2024828236
May 2024797927
Jun 2024646623
Jul 2024727325
Aug 2024727219
Sep 2024696929
Oct 2024888820
Nov 2024767831
Dec 2024878726
Jan 2025919132
Feb 2025616125
Mar 202510310341
Apr 202512812941
May 202510510933
Jun 2025525223
Total742475322356